U.S. Computational Biology Market Size, Share & Growth Report, 2033
The U.S. computational biology market size was valued at USD 2.85 billion in 2023 and is projected to surpass around USD 9.85 billion by 2033, registering a CAGR of 13.2% over the forecast period of 2024 to 2033.
The discoveries in genomics, molecular biology, cellular & tissue engineering, bio-imaging & new drug discovery, and delivery techniques are expected to create opportunities to improve diagnostic capabilities and expand therapeutic options.
Most of the clinical development in life sciences technologies for applications in oncology and infectious diseases is being carried out in the U.S. Successful completion of the human genome project paved the way for the development of personalized medicine approaches. Research, development, and commercialization of personalized medicine services and products occur faster in the U.S. than in other countries around the globe. Moreover, introducing automated solutions is anticipated to increase the adoption of life sciences tools among the end users. For instance, the Smart Extraction technology developed by Analytik Jena is used to extract high molecular weight DNA from a range of samples. This automated extraction and purification of nucleic acids simplifies the workflow and increases efficiency, yield, and DNA quality.
In 2023, the U.S. computational biology market accounted for over 46% of the global computational biology market. The presence of key biotechnology organizations, including the National Biotechnology Board (NBTB) and The Department of Biotechnology (DBT), encourages funding to support technological development and R&D for computational biology. Increasing need to study chronic diseases at a molecular level and formulate therapeutic solutions is expected to support these organizations to fund R&D programs. Government funding for life sciences research is projected to fuel market growth. Organizations, including the National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI), are actively involved in funding several life sciences projects. The NHGRI collaborates with scientists and researchers to deliver genomic research funds, such as the identification of genomic basis of diseases and determining the complexities of the human genome. NHGRI focuses on expanding genomic technology applications to improve patient care and benefit society.
| Report Attribute | Details |
| Market Size in 2024 | USD 3.23 Billion |
| Market Size by 2033 | USD 9.85 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 13.2% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Service, application, end-use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | DNAnexus, Inc.; Illumina, Inc.; Thermo Fisher Scientific, Inc.; Schrodinger, Inc.; Compugen, Aganitha AI Inc.; Genedata AG; QIAGEN; Simulations Plus, Inc.; Fios Genomics. |
The software platforms segment accounted for the largest market share of 39.12% in 2023 and is expected to grow at the fastest CAGR from 2024 to 2033. Software platforms comprise a diverse set of tools and technologies, including data analysis platforms, bioinformatics software, modeling and simulation software, and other technologies. These tools are crucial for the management and analysis of large volumes of biological data, including genomics, proteomics, and structural biology data. Furthermore, the growing demand for personalized medicines and rapid development in drug discovery & development are boosting the segment growth.
The infrastructure & hardware segment is expected to witness lucrative growth over the forecast period. The demand for robust hardware infrastructure services for supporting complex computations is anticipated to surge as computational biology research advances. Furthermore, the increasing investments by various healthcare organizations are expected to augment the segment growth during the forecast period. For instance, in February 2021, Rescale, a startup that focuses on enhancing scientific and engineering simulation through its software and hardware infrastructure, secured a funding of USD 50 million.
Clinical trials held the highest market share of 26.19% in 2023. This dominance is attributable to the increasing demand for drug discovery & development, personalized medicines, and target identification & validation. Furthermore, with the increase in accessibility of patient data, such as electronic health records and genomics, computational biology is being widely adopted for data interpretation and analysis for taking informed decisions in clinical trials.
The computational genomics segment is expected to grow at the fastest CAGR from 2024 to 2033. Computational genomics focuses on the interpretation and analysis of genomic data with the help of computational tools. Increasing prevalence of cancer has driven the development of advanced treatments, thereby fueling computational genomics demand in oncology.
The industrial segment accounted for the largest market share of 66.90% in 2023 owing to the increasing advancements in analysis and visualization of biological structures. With the growing demand to gain better insights into metabolic interactions within the biotechnology sectors, companies are harnessing the power of advanced technologies including artificial intelligence and machine learning.
Academics & research is expected to exhibit the fastest CAGR during the forecast period. Market growth is attributed to the increasing need for computational software to innovate genome analysis with the help of rising research and development activities conducted by various academic institutions and research organizations. Furthermore, the increase in collaborative investments and efforts between private and public entities to launch new research institutes is projected to boost segment growth.
In May 2023, Genialis unveiled the launch of Genialis Expressions 3.0. The software is designed to accelerate the process of discovering clinical and translational biomarkers. It also focuses on complex biological mechanisms for novel disease treatment methodologies.
In February 2023, Accenture announced its investment in Ocean Genomics, an AI-driven biotechnology company focusing on the development of advanced computational platforms. This deal was planned to support biotechnology companies for the discovery and development of personalized medicines.
U.S. Computational Biology Market Top Key Companies:
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Computational Biology market.
By Service
By Application
By End-use
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Service Segment
1.2.2. Application Segment
1.2.3. End-use Segment
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. U.S. Market: CAGR Calculation
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Growing Adoption Of Bioinformatics Technology
3.3.2. Advancements In Genomic Research
3.3.3. Increasing Demand For Personalized Medicines
3.4. Market Restraint Analysis
3.4.1. Lack of Skilled Professional
3.4.2. Data Privacy And Security Concerns
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Service Business Analysis
4.1. Computational Biology Market: Service Movement Analysis
4.2. Databases
4.2.1. Databases Market, 2021 - 2033
4.3. Infrastructure & Hardware
4.3.1. Infrastructure & Hardware, 2021 - 2033
4.4. Software Platform
4.4.1. Software Platform Market, 2021 - 2033
Chapter 5. Application Business Analysis
5.1. Computational Biology Market: Application Movement Analysis
5.2. Drug Discovery & Disease Modelling
5.2.1. Drug Discovery & Disease Modelling Market, 2021 - 2033
5.2.2. Target Identification
5.2.2.1. Target Identification Market, 2021 - 2033
5.2.3. Target Validation
5.2.3.1. Target Validation Market, 2021 - 2033
5.2.4. Lead Discovery
5.2.4.1. Lead Discovery Market, 2021 - 2033
5.2.5. Lead Optimization
5.2.5.1. Lead Optimization Market, 2021 - 2033
5.3. Preclinical Drug Development
5.3.1. Preclinical Drug Development Market, 2021 - 2033
5.3.2. Pharmacokinetics
5.3.2.1. Pharmacokinetics Market, 2021 - 2033
5.3.3. Pharmacodynamics
5.3.3.1. Pharmacodynamics Market, 2021 - 2033
5.4. Clinical Trials
5.4.1. Clinical Trials Market, 2021 - 2033
5.4.2. Phase I
5.4.2.1. Phase I Market, 2021 - 2033
5.4.3. Phase II
5.4.3.1. Phase II Market, 2021 - 2033
5.4.4. Phase III
5.4.4.1. Phase III Market, 2021 - 2033
5.4.5. Phase IV
5.4.5.1. Phase IV Market, 2021 - 2033
5.5. Computational Genomics
5.5.1. Computational Genomics Market, 2021 - 2033
5.6. Computational Proteomics
5.6.1. Computational Proteomics Market, 2021 - 2033
5.7. Others
5.7.1. Others Market, 2021 - 2033
Chapter 6. End-use Business Analysis
6.1. Computational Biology Market: End-use Movement Analysis
6.2. Academic & Research
6.2.1. Academic & Research Market, 2021 - 2033
6.3. Industrial
6.3.1. Industrial Market, 2021 - 2033
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Share/Position Analysis, 2023
7.4. Company Profiles/Listing
7.4.1. DNAnexus, Inc.
7.4.1.1. Company Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Illumina, Inc.
7.4.2.1. Company Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Thermo Fisher Scientific, Inc.
7.4.3.1. Company Overview
7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Schrödinger, Inc.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Compugen
7.4.5.1. Company Overview
7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Aganitha AI Inc.
7.4.6.1. Company Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Genedata AG
7.4.7.1. Company Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. QIAGEN
7.4.8.1. Company Overview
7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. SIMULATIONS PLUS
7.4.9.1. Company Overview
7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Fios Genomics
7.4.10.1. Company Overview
7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers